Theravance Inc. (NASDAQ:THRX) belongs to Healthcare sector. Its weekly performance is 4.89%. On last trading day company shares ended up $16.96. Theravance Inc. (NASDAQ:THRX) distance from 50-day simple moving average (SMA50) is -1.40%. On 13 July, Theravance Inc. (NASDAQ:THRX) announced the appointment of Michael E. Faerm as Senior Vice President and Chief Business Officer. Mr. Faerm reports directly to Michael W. Aguiar, Chief Executive Officer, and will lead Theravance’s growth strategy and corporate development initiatives beyond the company’s existing respiratory portfolio of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R).
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) shares decreased -2.44% in last trading session and ended the day at $4.00. RTTR return on assets is -370.40%. On 29 June, Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) announced the closing of its previously announced initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share. Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any.
On 14 July, Westpac Banking Corporation (NYSE:WBK) shares advanced 1.01% and was closed at $25.12. WBK EPS growth in last 5 year was 14.30%. Westpac Banking Corporation (NYSE:WBK) year to date (YTD) performance is -6.62%. Westpac Banking Corporation (NYSE:WBK) said that, it has sold its banking operations in Samoa, Tonga and the Cook Islands, but was unable to offload its Vanuatu arm due to Cyclone Pam, while it is still gaining approval for the sale of its Solomon Islands business.
CHC Group Ltd. (NYSE:HELI) ended the last trading day at $0.61. Company weekly volatility is calculated as 17.08% and price to cash ratio as 0.37. CHC Group Ltd. (NYSE:HELI) showed a weekly performance of -11.59%.On 29 June, CHC Group Ltd. (NYSE:HELI) reported revenue of $374 million and a net loss of $119 million for its fiscal 2015 fourth quarter, which ended April 30, 2015. Full-year consolidated revenue was $1.7 billion, a decline of 3 percent year-over-year, driven by the impact of currency translation as the U.S. dollar strengthened. On a constant currency basis, full year revenue increased 1 percent.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) shares advanced 9.60% in last trading session and ended the day at $4.68. OCRX return on assets is -52.50%. Ocera Therapeutics, Inc. (NASDAQ:OCRX) quarterly performance is 16.42%. Ocera Therapeutics, Inc. (NASDAQ:OCRX) was downgraded by Zacks from a “hold” rating to a “sell” rating in a research note issued on Monday.